UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2022 was $40.2 million, representing a 32% increase compared to Q2 2021 [28] - Gross profit was $24.6 million for Q2 2022, an increase of 24% from $19.7 million in Q2 2021 [28] - Gross profit margin was 61% in Q2 2022, down from 65% in Q2 2021 [28][29] - Adjusted gross profit margin was 64% in Q2 2022, compared to 65% in Q2 2021 [29] - Operating expenses increased to $25.5 million in Q2 2022, a 60% rise from $15.9 million in Q2 2021 [30] - Adjusted EBITDA for Q2 2022 was $4.8 million, slightly up from $4.7 million in Q2 2021 [32] Business Line Data and Key Metrics Changes - The installed base of instruments grew to 1,356 by the end of Q2 2022, with 130 instruments placed during the quarter [11] - The company expects reagents and recently launched cell orders to significantly contribute to future revenue growth [10] Market Data and Key Metrics Changes - The company has seen strong demand for its technology, with revenue growth driven by customer recognition of its advantages [12] - The CE marking for certain reagents allows clinical flow cytometry laboratories in the EU to purchase Cytek's products, expanding market opportunities [17] Company Strategy and Development Direction - Cytek aims to provide a complete cell analysis solution, focusing on instruments, reagents, software, and application services [9] - The company is committed to maintaining profitability and achieving long-term growth targets without the need for future capital raises [34] - Cytek is focused on expanding its offerings and validating its technology through peer-reviewed publications, which reached 768 by the end of the quarter [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges, including inflation and supply chain pressures [14] - The company anticipates continued strong demand and is optimistic about achieving its full-year revenue guidance of $160 million to $168 million [33][34] Other Important Information - The company appointed Todd Garland as Chief Commercial Officer, enhancing its leadership team [15] - Cytek participated in the Cyto conference, showcasing its technology and generating significant customer interest [19] Q&A Session Summary Question: Trends in reagent offerings demand - Management noted solid performance in reagent sales, with some currency headwinds impacting total revenue by approximately 3% to 5% [40] Question: CE marking and clinical applications in Europe - Management highlighted that CE marking opens new opportunities for clinical tenders in Europe, including certified instruments and reagents [42] Question: Progress on Cell Sorter and instrument categories - Management reported strong sales for the Cell Sorter and continued demand across all instrument types [47] Question: Drivers of gross margins - Management expects gross profit margins to gradually improve as higher-margin reagents are rolled out [48] Question: Inventory and free cash flow considerations - Management indicated that inventory levels have increased to $45 million, up from $32 million, to ensure sufficient parts are available for customer service [53] Question: Clinical applications beyond minimal residual disease - Management confirmed ongoing collaborations with clinical laboratories for various applications, including immuno-profiling [56] Question: Sales cycles and CapEx scrutiny in Europe - Management observed some delays in sales processes in Europe but remains optimistic about business recovery in the second half of the year [65] Question: Update on next-gen clinical flow instruments - Management stated that the development process for next-gen instruments is lengthy, with no new updates available [69]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRAN ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $35.1 million, a 44% increase compared to Q1 2021 [20] - Gross profit was $20.2 million for Q1 2022, up 39% from $14.5 million in Q1 2021, with a gross profit margin of 58% [21] - Operating expenses increased by 69% to $22.5 million in Q1 2022 from $13.4 million in Q1 2021 [22] - Net loss for Q1 2022 was $2.2 million compared to a net income of $0.1 million in Q1 2021 [24] - Adjusted EBITDA for Q1 2022 was $1.9 million, an increase from $1.1 million in Q1 2021 [24] - Full year 2022 revenue guidance is now expected to be closer to the high end of the range of $160 million to $168 million [25] Business Line Data and Key Metrics Changes - Service revenue more than doubled year-over-year as instruments came off warranty [20] - The installed base of instruments grew to 1,226, with 116 instruments placed in Q1 2022 [12] Market Data and Key Metrics Changes - Cytek's technology has been validated by 463 peer-reviewed publications, with 95 publications in Q1 2022, the highest in any quarter since the company's founding [16] Company Strategy and Development Direction - The company is focused on expanding its reagent business, which is expected to drive revenue growth over the next 3 to 5 years [11] - Cytek opened a new facility in Fremont, California, tripling its manufacturing capacity to meet global demand [14] - The company aims to maintain profitability while investing in core business and exploring M&A opportunities [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macro pressures, including supply chain disruptions and inflation, by leveraging a global workforce and maintaining inventory buffers [13] - The company remains optimistic about its growth trajectory and the demand for its instruments despite industry challenges [18] Other Important Information - Cytek will participate in the CYTO 2022 conference and host its first Analyst Day in New York City [27] Q&A Session Summary Question: Guidance on achieving the high end of revenue range - Management expects to carry momentum from Q1, with strong demand for key instruments and the reagent business [30] Question: Adoption metrics for the 25 color immuno-profiling kit - No specific metrics available at the moment, but updates may be provided at the upcoming analyst meeting [31] Question: Progress on MRD monitoring efforts - R&D is ongoing, with more data expected to be shared towards the end of the year [32] Question: Gross margin progression - Margins are expected to increase as the organization scales and the reagent business grows [34] Question: Instrument mix for the quarter - The Aurora remains the majority of instruments sold, followed by the Northern Lights family [35] Question: Customer feedback on the cell sorter - Initial setups take time, and significant results from publications may take 12 to 18 months [36] Question: Profile of early adopters in the reagent business - Customers include both pharma/biotech and academic sectors, with a high growth rate in reagent sales [40] Question: Impact of new competitive launches - No significant impact on business has been observed despite new competitors [41] Question: Operational challenges in China - The company has planned well for potential challenges and does not foresee significant impacts [44] Question: Sales ramp for the reagent business - The reagent sector is currently the fastest-growing part of the business [47]

PART I - FINANCIAL INFORMATION [Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Consolidated%20Financial%20Statements%20(Unaudited)) The unaudited consolidated financial statements detail the company's financial position, operations, and cash flows for the three months ended March 31, 2022, reflecting $35.1 million in revenue, a $2.2 million net loss, and $485.9 million in total assets [Consolidated Balance Sheets](index=3&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2022, total assets increased to $485.9 million, driven by inventories and lease assets, while total liabilities rose to $78.4 million, and equity remained stable at $407.4 million Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2022 (unaudited) | December 31, 2021 (audited) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $362,506 | $364,618 | | Inventories | $37,982 | $32,171 | | Operating lease right-of-use assets | $13,839 | $0 | | **Total Assets** | **$485,879** | **$463,305** | | **Liabilities & Equity** | | | | Total current liabilities | $42,803 | $33,181 | | Operating lease liability, non-current | $12,684 | $0 | | **Total Liabilities** | **$78,437** | **$57,920** | | **Total Stockholders' Equity** | **$407,442** | **$405,385** | [Consolidated Statements of Operations and Comprehensive (Loss) Income](index=4&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)) Total revenue increased 44% to $35.1 million for the three months ended March 31, 2022, but a significant rise in operating expenses led to a $2.2 million net loss compared to prior year net income Consolidated Statement of Operations Highlights (in thousands) | Account | Three months ended March 31, 2022 | Three months ended March 31, 2021 | | :--- | :--- | :--- | | **Total revenue, net** | **$35,064** | **$24,272** | | Gross profit | $20,177 | $14,486 | | Total operating expenses | $22,534 | $13,354 | | (Loss) income from operations | $(2,357) | $1,132 | | **Net (loss) income** | **$(2,158)** | **$102** | | Net (loss) income per share, diluted | $(0.02) | $0.00 | [Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity](index=5&type=section&id=Consolidated%20Statements%20of%20Redeemable%20Convertible%20Preferred%20Stock%20and%20Stockholders'%20Equity) Total stockholders' equity slightly increased to $407.4 million as of March 31, 2022, primarily due to stock-based compensation and option exercises offsetting the net loss - In Q1 2022, total stockholders' equity increased by approximately **$2.0 million**, primarily due to stock-based compensation of **$3.8 million** and proceeds from stock option exercises of **$0.4 million**, which was partially offset by a net loss of **$2.0 million**[16](index=16&type=chunk) [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was $1.5 million for the three months ended March 31, 2022, a reversal from the prior year, primarily due to increased inventories, resulting in a $2.1 million overall decrease in cash Consolidated Statement of Cash Flows Highlights (in thousands) | Activity | Three months ended March 31, 2022 | Three months ended March 31, 2021 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | $(1,480) | $1,935 | | Net cash used in investing activities | $(780) | $(138) | | Net cash provided by financing activities | $364 | $187 | | **Net (decrease) increase in cash** | **$(2,112)** | **$2,465** | | Cash and cash equivalents at end of period | $362,506 | $168,584 | [Notes to Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail accounting policies and financial statement items, covering the company's cell analysis business, 2021 IPO, lease accounting adoption, Tonbo acquisition, and other significant disclosures - The company is a cell analysis solutions company that develops and manufactures a full spectrum flow cytometry platform, including instruments (Aurora, Northern Lights), reagents, and software[26](index=26&type=chunk)[27](index=27&type=chunk) - In July 2021, the company completed its IPO, raising net proceeds of approximately **$215.7 million**, with all convertible preferred stock converted to common stock[29](index=29&type=chunk)[30](index=30&type=chunk) - The company adopted the new lease accounting standard, Topic 842, on January 1, 2022, resulting in the recognition of operating lease right-of-use assets of **$14.6 million** and lease liabilities of **$15.2 million**[87](index=87&type=chunk)[93](index=93&type=chunk) - In November 2021, the company acquired the reagents business of Tonbo Biotechnologies for **$17 million**, adding a portfolio of life science research reagents and recognizing **$9.7 million** in goodwill[118](index=118&type=chunk)[121](index=121&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2022 financial results, noting a 44% revenue increase to $35.1 million driven by product demand, but a $2.2 million net loss due to strategic investments in R&D and sales - Total revenue for Q1 2022 was **$35.1 million**, a **44% increase** from **$24.3 million** in Q1 2021, primarily due to continued demand for the company's product portfolio[186](index=186&type=chunk)[222](index=222&type=chunk) - The company reported a net loss of **$2.2 million** in Q1 2022, compared to a net income of **$0.1 million** in Q1 2021, resulting from increased operating expenses in R&D, sales & marketing, and G&A[191](index=191&type=chunk)[221](index=221&type=chunk) - The company's installed base of instruments grew to **1,226** as of March 31, 2022, up from **1,110** at the end of 2021[205](index=205&type=chunk) - As of March 31, 2022, the company had cash and cash equivalents of **$362.5 million**, which management believes is sufficient to meet working capital and capital expenditure needs for at least the next 12 months[242](index=242&type=chunk)[245](index=245&type=chunk) [Results of Operations](index=33&type=section&id=Results%20of%20operations) Total revenue increased 44% to $35.1 million in Q1 2022, but a slight gross margin decrease and a 69% surge in operating expenses led to an operating loss compared to prior year income Revenue Comparison (in thousands) | Revenue Type | Q1 2022 | Q1 2021 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Product | $31,481 | $22,700 | $8,781 | 39% | | Service | $3,583 | $1,572 | $2,011 | 128% | | **Total** | **$35,064** | **$24,272** | **$10,792** | **44%** | - Gross margin decreased to **58%** in Q1 2022 from **60%** in Q1 2021, primarily due to increased material costs and higher service and manufacturing headcount[227](index=227&type=chunk) Operating Expense Comparison (in thousands) | Expense Category | Q1 2022 | Q1 2021 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $8,025 | $5,094 | $2,931 | 58% | | Sales and marketing | $6,960 | $4,277 | $2,683 | 63% | | General and administrative | $7,549 | $3,983 | $3,566 | 90% | | **Total** | **$22,534** | **$13,354** | **$9,180** | **69%** | [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20capital%20resources) As of March 31, 2022, the company held $362.5 million in cash, primarily from securities sales and IPO proceeds, with net cash used in operations at $1.5 million due to increased inventory - The company's primary sources of capital have been sales of securities and revenue from product sales, with the July 2021 IPO resulting in net proceeds of approximately **$215.7 million**[246](index=246&type=chunk) - Cash used in operating activities was **$1.5 million** in Q1 2022, compared to cash provided by operating activities of **$1.9 million** in Q1 2021, driven by a **$5.9 million** increase in inventories and a **$4.2 million** increase in prepaid expenses and other assets[250](index=250&type=chunk)[251](index=251&type=chunk) - The company fully repaid its **$4.1 million** Paycheck Protection Program (PPP) loan on May 4, 2021[247](index=247&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks primarily from foreign currency fluctuations in renminbi and euro, while interest rate risk is minimal due to short-term cash holdings, with no hedging currently employed - The company's primary market risk exposures are from foreign currency exchange rates (primarily renminbi and euro) and interest rates[262](index=262&type=chunk)[265](index=265&type=chunk) - Interest rate risk is considered low as cash and cash equivalents of **$362.5 million** are held in short-term, variable-rate money market funds and bank deposits[263](index=263&type=chunk)[264](index=264&type=chunk) - The company does not currently use hedging instruments to mitigate foreign currency risk but will reassess this approach as international operations grow[266](index=266&type=chunk) [Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls were ineffective as of March 31, 2022, due to material weaknesses related to insufficient personnel and inadequate policies, with remediation efforts underway - Management concluded that disclosure controls and procedures were not effective as of March 31, 2022, due to existing material weaknesses[268](index=268&type=chunk) - Material weaknesses identified relate to (i) insufficient qualified personnel in accounting and IT and (ii) lack of formal policies and procedures for applying U.S. GAAP and designing appropriate IT and financial reporting controls[269](index=269&type=chunk) - Remediation efforts are underway, including engaging external consultants, hiring qualified personnel, formalizing the internal controls environment, and strengthening IT general controls[270](index=270&type=chunk)[272](index=272&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to materially adversely affect its business, operating results, or financial condition - The company is not presently a party to any legal proceedings that would individually or in aggregate have a material adverse effect on its business[276](index=276&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) This section outlines various risks, including limited operating history, product dependence, supply chain reliance, manufacturing challenges, regulatory oversight, intellectual property concerns, competition, and internal control weaknesses - The company has a limited operating history and is highly dependent on a limited number of products, primarily the Aurora and Northern Lights systems[279](index=279&type=chunk)[283](index=283&type=chunk) - Reliance on single and sole source suppliers for key components like lasers and semiconductors poses a significant risk to the supply chain and manufacturing[279](index=279&type=chunk)[286](index=286&type=chunk) - The company has identified material weaknesses in its internal control over financial reporting, which could impact the accuracy and timeliness of financial reports[281](index=281&type=chunk)[348](index=348&type=chunk) - The market for cell analysis is highly competitive, with competitors including large, well-resourced companies like Becton, Dickinson and Company (BD), Danaher, and Thermo Fisher Scientific[312](index=312&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=80&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered equity sales during the period and confirmed no material change in the use of proceeds from its July 2021 IPO - There were no unregistered sales of equity securities in the quarter[520](index=520&type=chunk) - There has been no material change in the use of proceeds from the company's IPO, which were registered under Form S-1 (Registration No. 333-257663)[523](index=523&type=chunk) [Defaults Upon Senior Securities](index=81&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities reported during the period - None[525](index=525&type=chunk) [Mine Safety Disclosures](index=81&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - Not applicable[527](index=527&type=chunk) [Other Information](index=81&type=section&id=Item%205.%20Other%20Information) No other information is reported for this item - None[529](index=529&type=chunk) [Exhibits](index=82&type=section&id=Item%2015.%20Exhibits) This section lists exhibits filed with the quarterly report, including corporate documents, CEO and CFO certifications, and Inline XBRL documents - Exhibits filed include CEO and CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[532](index=532&type=chunk)[533](index=533&type=chunk)[534](index=534&type=chunk) - The report includes Inline XBRL instance, schema, calculation, definition, label, and presentation linkbase documents[536](index=536&type=chunk)[537](index=537&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2021 was $38.9 million, a 27% increase compared to Q4 2020, contributing to a full-year revenue growth of 38% in 2021 [29] - Gross profit for Q4 2021 was $23.6 million, a 22% increase from $19.4 million in Q4 2020, with a gross profit margin of 61% [30] - Operating expenses rose to $22.3 million in Q4 2021, a 92% increase from $11.6 million in Q4 2020, primarily due to costs associated with business growth and public company operations [31] - Net income for Q4 2021 was $0.3 million, down from $5.6 million in Q4 2020 [33] Business Line Data and Key Metrics Changes - The installed base of instruments grew to 1,110 by the end of 2021, with 140 instruments placed in Q4 2021 [18] - The company began shipping cell sorters, which are expected to drive revenue growth alongside reagents over the next three to five years [16] Market Data and Key Metrics Changes - The company made progress in regulated clinical markets, including obtaining certifications in China and the EU for its products [20][21] - The technology has been validated by 385 peer-reviewed publications, with significant research focus areas including infectious disease and oncology [25] Company Strategy and Development Direction - The company aims to become the full cell analysis solutions partner of choice in the life sciences field, leveraging its novel technology to drive innovation [42] - A new facility in Fremont has been opened to triple manufacturing capacity, supporting growing global demand [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2022 with a strong position, expecting full-year revenue between $160 million and $168 million [35] - The company plans to increase capital and operating investments in sales, marketing, and R&D by 55% to 60% to support growth initiatives [37] Other Important Information - The integration of Tonbo Biosciences' business is largely complete, enhancing the company's reagent portfolio [22] - The company is focused on developing new reagent kits to meet customer demand and streamline research workflows [59] Q&A Session Summary Question: Impact of pandemic on capital expenditures - Management noted minimal impact in the U.S. and Europe, but some delays in the APAC region [45] Question: Demand for cell sorters and customer mix - Demand for cell sorters is strong, with existing customers often purchasing in pairs with analyzers [48] Question: Guidance range explanation - The guidance range reflects a combination of instrument sales, reagents, and service revenue, with confidence in both ends of the range [51] Question: Instrument versus consumable mix - The majority of revenue is expected to come from instruments, with growing contributions from reagents and service revenues [52] Question: Adoption cycle for reagents - Early customers are leveraging available reagents, with a focus on developing optimized panels and kits [57] Question: Competitive landscape and technology advantage - Management acknowledged awareness of competitor launches but emphasized the difficulty in assessing impact until products are in the market [61] Question: Total addressable market expansion - Management highlighted key application areas supported by their tools, indicating potential for market expansion [63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CTKB The Nasdaq Global Select Market Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Wenbin Jiang - Chief Executive Officer Patrik Jeanmonod - Chief Financial Officer Conference Call Participants Max Masucci - Cowen and Company Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CTKB The Nasdaq Global Select Market Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...